“…Reactive astrogliosis is observed in virtually all neurological conditions, including epilepsy ( Steinhäuser et al, 2015 ), neoplastic disease ( Priego et al, 2018 ; Heiland et al, 2019 ), demyelination ( Woodruff and Franklin, 1999 ; Williams et al, 2007 ; Tassoni et al, 2019 ; Rawji et al, 2020 ), traumatic injury ( Faulkner et al, 2004 ; Filous and Silver, 2016 ; Boghdadi et al, 2020a ), neurodegeneration ( Vargas et al, 2008 ; Ben Haim et al, 2015 ), and ischemic stroke ( Zhao and Rempe, 2010 ; Zamanian et al, 2012 ; Rakers et al, 2019 ), as well as microbial CNS infections ( Drögemüller et al, 2008 ; Soung and Klein, 2018 ; Geyer et al, 2019 ) and neurotoxin exposure ( O’Callaghan et al, 2014 ; Wheeler et al, 2019 ). Reactive astrogliosis enables astrocytes to serve key roles in CNS pathological states, including metabolic support of vulnerable neurons, regulation of BBB permeability, remodeling of extracellular matrix (ECM), mobilizing progenitors, as well as immunomodulation, synaptic remodeling, and neurite outgrowth ( Woodruff et al, 2004 ; Sofroniew and Vinters, 2010a ; Anderson et al, 2014 ; Pekny and Pekna, 2014 ; Escartin et al, 2019 , 2021 ).…”